David Alderton

Centre for Human Genetics

Papers

1

Total Citations

57

H-Index

1

About

Dr. David Alderton is a leading figure in recombinant protein production, whose work has streamlined one of biotechnology’s most critical tools: the baculovirus expression vector system (BEVS). His primary research focuses on developing high-throughput, scalable methods for protein expression in insect cells, addressing a long-standing bottleneck in structural biology and biopharmaceutical development. Alderton’s landmark 2008 paper, “Generation of baculovirus vectors for the high‐throughput production of proteins in insect cells,” has garnered 57 citations and introduced an innovative bacmid vector that eliminates the need for complex selection steps. This breakthrough simplified the multi-parallel production process, making BEVS more accessible for large-scale screening and enabling researchers to produce difficult-to-express proteins with greater efficiency. By removing inherent technical hurdles, Alderton’s contributions have accelerated drug discovery and structural genomics, providing a robust platform for producing everything from therapeutic enzymes to vaccine antigens. His work remains a cornerstone for laboratories seeking reliable, high-yield protein expression, cementing his reputation as an innovator in molecular biotechnology.

Research Focus

Key Achievements

1
H-Index
1
Papers
57
Total Citations
57
Avg Citations/Paper
🏆 Most Cited Paper
Generation of baculovirus vectors for the high‐throughput production of proteins in insect cells
57 citations · 2008
📈 Most Prolific Year: 2008 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Centre for Human Genetics

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago